{"success":true,"data":{"pressRelease":{"id":"164036","rtpr_id":"nGNXbNhQJs-20261008","ticker":"LXEO","exchange":"NASDAQ","all_tickers":["LXEO"],"title":"Lexeo Therapeutics to Participate in the Chardan Healthcare Conference","author":"Globe Newswire","published_at":"2026-10-08T11:00:01.608Z","article_body":"NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=hVT0l3nRVQi2unYOS-vj6prGeyj1uH-OJg5gEOE5W5DWK60RSUs5jrT1rI0YrlRp1q-Og0hXYYUDOUmkBH6A6NH9Mrby8Z6eN9dy0bWJHT0=)\n(Nasdaq: LXEO) a clinical stage company focused on reshaping the path of\ngenetic diseases with high unmet need, today announced that the Company will\nparticipate in a fireside chat at Chardan’s 10th Annual Healthcare\nConference on October 20, 2026 at 9:30am ET.\n\nThe event will be webcast live under the Events & Presentations\n(https://www.globenewswire.com/Tracker?data=MPBTeBzL259MuKwJJf3GIzE3ja8JupZBMohXLM_vjnk4M2UpfiV1Z6bsUcILEXmSyTI-BQQ9HBqK8OgJwVUaBw4SD5j-ATk5eHRw01gSrc9ypyVfeIQ6nrRo3dEcna9LBgqBmetJ9PHu8IXG9W4CPg==)\ntab in the Investors section of the Company’s website. A replay of the\nwebcast will be available on the Lexeo website following the presentation.\n\nAbout Lexeo Therapeutics\nLexeo Therapeutics is a New York City-based, clinical stage company dedicated\nto reshaping the path of genetic disease. By advancing pioneering science,\nLexeo seeks to set a new standard in the treatment of cardiovascular and\nneurological genetic diseases, charting the path to patient outcomes once\nthought out of reach. The Company is advancing a portfolio of therapeutic\ncandidates designed to address the underlying genetic causes of disease,\nincluding LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2)\narrhythmogenic cardiomyopathy, and others in devastating diseases with high\nunmet need.\n\nMedia Response:\nMedia@lexeotx.com\n\nInvestor Response:\nAshley Kaplowitz\nakaplowitz@lexeotx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/85c275df-e665-426f-a3bc-4a839a0b34d3)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXbNhQJs-20261008","title":"Lexeo Therapeutics to Participate in the Chardan Healthcare Conference","author":"Globe Newswire","ticker":"LXEO","created":"2026-10-08T11:00:01.608Z","tickers":["LXEO"],"exchange":"NASDAQ","article_body":"NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc.\n(https://www.globenewswire.com/Tracker?data=hVT0l3nRVQi2unYOS-vj6prGeyj1uH-OJg5gEOE5W5DWK60RSUs5jrT1rI0YrlRp1q-Og0hXYYUDOUmkBH6A6NH9Mrby8Z6eN9dy0bWJHT0=)\n(Nasdaq: LXEO) a clinical stage company focused on reshaping the path of\ngenetic diseases with high unmet need, today announced that the Company will\nparticipate in a fireside chat at Chardan’s 10th Annual Healthcare\nConference on October 20, 2026 at 9:30am ET.\n\nThe event will be webcast live under the Events & Presentations\n(https://www.globenewswire.com/Tracker?data=MPBTeBzL259MuKwJJf3GIzE3ja8JupZBMohXLM_vjnk4M2UpfiV1Z6bsUcILEXmSyTI-BQQ9HBqK8OgJwVUaBw4SD5j-ATk5eHRw01gSrc9ypyVfeIQ6nrRo3dEcna9LBgqBmetJ9PHu8IXG9W4CPg==)\ntab in the Investors section of the Company’s website. A replay of the\nwebcast will be available on the Lexeo website following the presentation.\n\nAbout Lexeo Therapeutics\nLexeo Therapeutics is a New York City-based, clinical stage company dedicated\nto reshaping the path of genetic disease. By advancing pioneering science,\nLexeo seeks to set a new standard in the treatment of cardiovascular and\nneurological genetic diseases, charting the path to patient outcomes once\nthought out of reach. The Company is advancing a portfolio of therapeutic\ncandidates designed to address the underlying genetic causes of disease,\nincluding LX2006 for Friedreich ataxia (FA), LX2020 for plakophilin-2 (PKP2)\narrhythmogenic cardiomyopathy, and others in devastating diseases with high\nunmet need.\n\nMedia Response:\nMedia@lexeotx.com\n\nInvestor Response:\nAshley Kaplowitz\nakaplowitz@lexeotx.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/85c275df-e665-426f-a3bc-4a839a0b34d3)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-10-08T11:00:01.647480669Z","server_sent_at_ms":1791457201647},"received_at":"2026-10-08T11:00:01.697Z","source_url":null},"analysis":{"id":"152467","press_release_id":"164036","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Lexeo Therapeutics will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.\n\nThe presentation will be webcast live on the company's investor relations website, with a replay available afterward.\n\nLexeo is a clinical-stage company developing gene therapy candidates including LX2006 for Friedreich ataxia and LX2020 for PKP2 arrhythmogenic cardiomyopathy.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance -- no action needed."},"keyFigures":{},"namedEntities":{"people":[{"name":"Ashley Kaplowitz","role":"Investor Relations contact"}],"products":["LX2006","LX2020"],"companies":[{"name":"Lexeo Therapeutics, Inc.","ticker":"LXEO"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine announcement of conference participation with no new financial, clinical, or regulatory information disclosed."},"tickerRelevance":{"others":[],"primary":"LXEO"},"globalImportance":5,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"conference-scheduling-notice","issuerAuthored":true}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Lexeo Therapeutics will participate in a fireside chat at Chardan's 10th Annual Healthcare Conference on October 20, 2026 at 9:30am ET.\n\nThe presentation will be webcast live on the company's investor relations website, with a replay available afterward.\n\nLexeo is a clinical-stage company developing gene therapy candidates including LX2006 for Friedreich ataxia and LX2020 for PKP2 arrhythmogenic cardiomyopathy.","key_figures":{},"named_entities":{"people":[{"name":"Ashley Kaplowitz","role":"Investor Relations contact"}],"products":["LX2006","LX2020"],"companies":[{"name":"Lexeo Therapeutics, Inc.","ticker":"LXEO"},{"name":"Chardan","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:5c812bd9e28b810d","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-10-08T11:00:18.133Z","global_importance":5,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"conference-scheduling-notice","issuerAuthored":true}},"durationMs":3971,"modelName":"glm-5.3-flashx"}}